Key facts
- Feldan Therapeutics’s last known valuation is $40.3M.
- It has raised $39.2M; the latest was Later Stage VC ($23.3M) in Aug 2024.
- Notable investors include Investissement Quebec, Fonds de solidarite FTQ, AQC Capital, Amgen Ventures, Anges Québec — 14 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 14 names
- ·Watchlist + deal alerts for Feldan Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Feldan Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Feldan Therapeutics
Operator of a peptide-based intracellular delivery platform designed to enable access to therapeutic targets within cells for the treatment of serious diseases. The company offers a proprietary shuttle technology that facilitates safe, rapid, and efficient delivery of antisense oligonucleotides, enabling patients with skin and lung diseases to benefit from novel therapies that reach previously inaccessible intracellular targets.
- Sector
- Healthcare
- HQ
- Quebec, Canada
- Founded
- 2007
- Employees
- 43
- Website
- feldan.com/
- Ownership
- Privately Held (backing)
Feldan Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Feldan Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Feldan Therapeutics in its N-PORT filings yet. We sweep new filings monthly.